HC Wainwright assumed coverage on shares of Predictive Oncology (NASDAQ:POAI – Free Report) in a research report report published on Monday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $3.00 price target on the medical instruments supplier’s stock. HC Wainwright also issued estimates for Predictive Oncology’s Q3 2024 earnings at ($0.32) EPS, Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($2.03) EPS, Q1 2025 earnings at ($0.10) EPS, Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at $0.05 EPS, FY2025 earnings at ($0.16) EPS, FY2026 earnings at $0.05 EPS, FY2027 earnings at $0.25 EPS and FY2028 earnings at $0.43 EPS.
Predictive Oncology Price Performance
Shares of Predictive Oncology stock opened at $0.97 on Monday. The firm has a market cap of $3.98 million, a price-to-earnings ratio of -0.27 and a beta of 1.15. Predictive Oncology has a 52-week low of $0.85 and a 52-week high of $4.70. The stock has a 50-day simple moving average of $1.07 and a 200-day simple moving average of $1.80.
Institutional Investors Weigh In On Predictive Oncology
A hedge fund recently bought a new stake in Predictive Oncology stock. Carnegie Mellon University purchased a new stake in shares of Predictive Oncology Inc. (NASDAQ:POAI – Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 10,358 shares of the medical instruments supplier’s stock, valued at approximately $34,000. Predictive Oncology comprises approximately 0.0% of Carnegie Mellon University’s holdings, making the stock its 5th biggest position. Carnegie Mellon University owned approximately 0.26% of Predictive Oncology as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 9.04% of the company’s stock.
About Predictive Oncology
Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.
Recommended Stories
- Five stocks we like better than Predictive Oncology
- How Investors Can Find the Best Cheap Dividend Stocks
- Target Hits the Mark: Q2 Earnings Exceed Expectations
- What Are Some of the Best Large-Cap Stocks to Buy?
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
- Ride Out The Recession With These Dividend Kings
- Stanley Druckenmiller’s Latest Bet: MELI—Should You Follow Suit?
Receive News & Ratings for Predictive Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Predictive Oncology and related companies with MarketBeat.com's FREE daily email newsletter.